The First Affiliated Hospital of Harbin Medical University

The First Affiliated Hospital of Harbin Medical University is a comprehensive tertiary Grade-A hospital integrating medical care, teaching, and research. Founded in 1949, it is the earliest medical school affiliated hospital in Heilongjiang Province. The hospital has two campuses, 54 clinical departments, 120 wards, 4,800 beds, nearly 3.72 million annual outpatient visits, and over 5,700 employees including 147 doctoral supervisors and 377 master's supervisors. The hospital holds 20 National Clinical Key Specialty construction projects, 7 Heilongjiang Province首批 clinical research centers, and 23 provincial medical quality control centers. Hematology and General Surgery are leading specialties, with General Surgery as a national key cultivation discipline and Integrated Traditional Chinese and Western Medicine as a National Regional TCM Diagnosis and Treatment Center cultivation unit. China's first corneal transplant surgery was performed here. Arsenic Trioxide Injection was rated as a National Class II New Drug, recognized as one of China's Top Ten Technological Inventions of the 20th Century, and won the 2020 Future Science Prize in Life Sciences. The hospital undertakes healthcare and diagnosis tasks for vice-provincial level and above leaders and important foreign guests, with an International Medicine Department maintaining friendly cooperation with over 30 countries and regions including the United States, Japan, Canada, Australia, the United Kingdom, France, the Netherlands, Italy, Russia, Hong Kong, Macau, and Taiwan. It has achieved A+ in the national tertiary public hospital performance assessment for 5 consecutive years, ranking 55th nationwide among general hospitals in 2022.